Uber and DoorDash have held exploratory talks with investors in Delivery Hero ahead of a potential takeover bid, according to a report.
Multiple investors indicated they would seek a price above 40 euros per share for the German food delivery firm.
Uber and DoorDash Explore Delivery Hero Bid
Uber and DoorDash are exploring a bid for Delivery Hero, with investors seeking over 40 euros per share. Read more on Bond.az.
More News
DeepSeek cuts V4-Pro AI model price by 75%
DeepSeek permanently reduces V4-Pro AI model price by 75%, dropping to a quarter of original cost.
Invest at Market Highs: UBS Top Pick
UBS analysts recommend ASML stock at market highs. Learn about the reasons, forecasts, and advantages of High NA technology.
Nvidia $200 bln CPU market includes China
Nvidia CEO Jensen Huang confirms $200 billion CPU market forecast includes China, signaling long-term demand despite U.S.-China tech tensions.
Zoom Nets $1B Return on Anthropic Bet Ahead of New Round
Zoom secures over $1 billion return on its 2023 Anthropic investment. The $51 million stake is now worth $1.3 billion.
Fenwick to pay $54M to settle FTX lawsuit
Fenwick & West agrees to $54M settlement over FTX fraud allegations. Court approval pending.
Boeing Cleared in 737 MAX Fraud Case
Boeing found not guilty of fraud in LOT Polish Airlines 737 MAX lawsuit. Jury clears company of hiding safety flaws linked to fatal crashes.
SpaceX Starship V3 blasts off in debut test
SpaceX's Starship V3 completed its first test flight from Texas. Key upgrades include new engines and heat shield. No recovery attempted.
Blue Origin expands Florida campus with $600M facility
Blue Origin expands its Florida campus with a $600 million facility, creating 500 aerospace jobs.
US warns of China role in Argentina bid
U.S. House committee chair warns of Chinese influence in Argentina's $10 billion Parana River dredging contract bid.
Senior Walmart executives depart amid reshuffling
Walmart sees executive departures amid restructuring under new CEO John Furner.
Gilead wins FDA approval for first hepatitis delta treatment
Gilead Sciences gets FDA approval for Hepcludex, the first treatment for chronic hepatitis delta virus. Shares rose over 2%.
BP presents revised labor proposal at Whiting refinery
BP's revised labor proposal at Whiting refinery includes pay raises and lump sum payments, addressing union concerns.
...